SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.
Ann Intern Med
; 174(10): 1404-1408, 2021 Oct.
Article
in En
| MEDLINE
| ID: mdl-34280332
ABSTRACT
BACKGROUND:
With the emergency use authorization of multiple vaccines against SARS-CoV-2 infection, data are urgently needed to determine their effectiveness in a real-world setting.OBJECTIVE:
To evaluate the short-term effectiveness of vaccines in preventing SARS-CoV-2 infection.DESIGN:
Test-negative case-control study using conditional logistic regression.SETTING:
U.S. Department of Veterans Affairs health care system.PARTICIPANTS:
All veterans who had testing for SARS-CoV-2 infection between 15 December 2020 and 4 March 2021 and no confirmed infection before 15 December 2020. INTERVENTION SARS-CoV-2 vaccination with either the BNT-162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine as part of routine clinical care. MEASUREMENTS Effectiveness of vaccination against confirmed SARS-CoV-2 infection.RESULTS:
Among 54 360 persons who tested positive and 54 360 propensity score-matched control participants, the median age was 61 years, 83.6% were male, and 62% were White. Median body mass index was 31 kg/m2 among those who tested positive and 30 kg/m2 among those who tested negative. Among those who tested positive, 9800 (18.0%) had been vaccinated; among those who tested negative, 17 825 (32.8%) had been vaccinated. Overall vaccine effectiveness 7 or more days after the second dose was 97.1% (95% CI, 96.6% to 97.5%). Effectiveness was 96.2% (CI, 95.5% to 96.9%) for the Pfizer-BioNTech BNT-162b2 vaccine and 98.2% (CI, 97.5% to 98.6%) for the Moderna mRNA-1273 vaccine. Effectiveness remained above 95% regardless of age group, sex, race, or presence of comorbidities.LIMITATIONS:
Predominantly male population; lack of data on disease severity, mortality, and effectiveness by SARS-CoV-2 variants of concern; and short-term follow-up.CONCLUSION:
Currently used vaccines against SARS-CoV-2 infection are highly effective in preventing confirmed infection in a high-risk population in a real-world setting. PRIMARY FUNDING SOURCE None.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Veterans
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Intern Med
Year:
2021
Type:
Article